Older patients with acute myeloid leukemia (AML) have a dismal prognosis, even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had promising efficacy in a previous phase ...

Relapse remains a leading cause for treatment failure after hematopoietic cell transplantation (HCT) in patients with intermediate- or high-risk myelodysplastic syndrome (MDS). To discern the impact ...

Herein, we report the results of an open-label, single-center phase II clinical trial evaluating the efficacy of azacitidine in the setting of MRD-triggered (decrease of CD34 + donor chimerism below ...

The chemotherapy drug azacitidine, a frontline treatment for blood cancers such as myelodysplastic syndromes and acute myeloid leukemia, kills cancer cells partly by damaging their RNA rather than ...

ORLANDO, Florida — For the first time, there is a maintenance therapy for patients with acute myeloid leukemia (AML) in remission that can improve overall survival — a new oral formulation of an old ...

The appraisal committee considered evidence submitted by Celgene and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence. The ...

The Committee heard from the clinical specialists that current practice includes the use of best supportive care and, for some patients who are able to tolerate it, low- or standard-dose chemotherapy.

An oral presentation will highlight results from the Phase 2 ASTX030-01 trial, a multicenter, randomized, open-label, crossover trial comparing the all-oral combination of azacitidine and cedazuridine ...

Myelodysplastic syndromes (MDS) are a diverse group of bone marrow disorders in which immature stem cells do not mature to become red blood cells, white blood cells or platelets. Patients with ...

Review the side-effects of Azacitidine as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Compared with placebo and azacitidine, the combination of ivosidenib and azacitidine prolongs event-free survival for patients with newly diagnosed IDH1-mutated acute myeloid leukemia who are ...

Safety and efficacy of eganelisib in adults with higher-risk myelodysplastic syndrome (HR-MDS) or relapsed/refractory (R/R) acute myeloid leukemia (AML). This is an ASCO Meeting Abstract from the 2026 ...